Drug intelligence / Profile preview

osiris

Development stage
Unknown
Lead developer
ALK Abelló
Modality
Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
Administration
Sublingual
01

Overview

Osiris is a sublingual allergen immunotherapy (SLIT) liquid formulation developed by ALK-Abelló for the treatment of allergic rhinitis and allergic rhinoconjunctivitis. It is marketed under the brand name Osiris in France and as SLITone or SLIToneULTRA in other European countries. Osiris is available in several formulations targeting different allergens, including a 5-grass-pollen mix (comprising equal parts of *Dactylis glomerata*, *Phleum pratense*, *Lolium perenne*, *Anthoxanthum odoratum*, and *Poa pratensis*), a single grass pollen (*Phleum pratense*), house dust mites (*Dermatophagoides pteronyssinus* and *Dermatophagoides farinae*), and cat dander. The therapy works by delivering standardized allergen extracts sublingually to desensitize the immune system, inducing allergen-specific IgG4 antibodies and IgE-blocking factors to reduce allergic symptoms upon subsequent exposure.

Brand names
OsirisSLIToneSLIToneULTRA
Other names
5-grass-pollen-mix SLIT dropsPhleum pratense sublingual solutionhouse dust mite allergen extractcat allergen extract
02

Targets

House dust mite allergen protein

Beyond the preview

Go deeper on osiris.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on osiris.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call